Article citationsMore>>

Carden, C.P., Sarker, D., Postel-Vinay, S., Yap, T.A., Attard, G., Banerji, U., et al. (2010) Can Molecular Biomarker-Based Patient Selection in Phase I Trials Accelerate Anticancer Drug Development? Drug Discovery Today, 15, 88-97. http://dx.doi.org/10.1016/j.drudis.2009.11.006

has been cited by the following article:

• TITLE: Missing the Target?—Targeted Therapy in Small Cell Lung Cancer

  AUTHORS: Karin R. Purshouse

  KEYWORDS: Oncology, Small Cell Lung Cancer, Targeted Therapy, Drug Development

  JOURNAL NAME: Advances in Lung Cancer, Vol.3 No.3, August 22, 2014

  ABSTRACT: Small cell lung cancer [SCLC] is a devastating form of cancer, with most patients harbouring extensive disease at diagnosis and survival of less than 5% at five years. Progress in novel therapies has been limited. This specialist review explores current targeted therapy options and potential areas of development.